Skip to main content

Table 4 Clinical studies in Lung Cancer

From: Combination of CTLA-4 and PD-1 blockers for treatment of cancer

Patients

Trial, ID

Follow-up

Outcomes

Reference

Advanced NSCLC

Phase 1b

NCT02000947

24 weeks

ORR, 23%

Grade 3-4 AEs, 35%

Antonia et al 2016

Treatment relapsed advanced SCLC

Phase 1/2

NCT01928394

≥ 12 weeks

ORR, 23%

Median OS, 7.7 months

1-year OS rate, 43%

Median PFS, 2.6 months

1-year PFS rate, 19%

Grade 3-4 AEs, 30%

Antonia et al 2016

Untreated advanced NSCLC

Phase 1 NCT01454102

> 9 months

ORR, 47%

Median PFS, 8.1 months

24-week PFS rate, 68%

Grade 3-4 AEs, 37%

Hellman et al 2017

Untreated advanced NSCLC

Phase 2

NCT02659059

≥ 6 months

In patients with TMB≥10 mutations/megabase

ORR, 44%

Median PFS, 7.1 months

6-month PFS rate, 55%

Grade 3-4 AEs, 29% (all patients)

Ready et al 2019

Untreated advanced NSCLC

Phase 3

NCT02477826

> 11 months

In patients with TMB≥10 mutations/megabase

ORR, 45%

Median PFS, 7.2 months

12-month PFS rate, 43%

HR for disease progression or death, 0.58

Grade 3-4 AEs, 31%

Hellman et al 2018